Clinical correlations between treatment with anticoagulants/antiaggregants and late rectal toxicity after radiotherapy for prostate cancer.
OBJECTIVE
To assess variables related to grade 2 or higher late rectal toxicity (LRT) in prostate cancer treated with external radiotherapy.


METHODS
A retrospective analysis was carried out of 232 patients with T1-T3 prostate cancer treated with 3-dimensional conformal radiotherapy (3DCRT) (106 patients) or intensity modulated radiotherapy (IMRT) (126 patients) between June 2000 and May 2007. One hundred and seventy-seven patients received androgen deprivation therapy (ADT); fifty patients used anticoagulants/antiaggregants for vascular disease.


RESULTS
The median follow-up was 31 months (range, 6-79). At 5 years, the cumulative incidence of grade 2 or 3 LRT was 5.6% . On multivariate analysis, medication with anticoagulants/antiaggregants was correlated with grade 2 or 3 LRT (p=0.027), whereas age, National Comprehensive Cancer Network risk group classification, use of ADT, radiotherapy technique (3DCRT vs. IMRT) and total irradiated dose were not.


CONCLUSIONS
Treatment with anticoagulants/antiaggregants appears to be a factor in grade 2 or 3 LRT.
Takeda
Ken
K
Department of Radiation Oncology, Tohoku University School of Medicine, 1-1 Seiryomachi, Aobaku, Sendaishi 980-8574, Japan. takedak41@yahoo.co.jp
Ogawa
Yoshihiro
Y
Ariga
Hisanori
H
Koto
Masashi
M
Sakayauchi
Toru
T
Fujimoto
Keisuke
K
Narazaki
Kakutaro
K
Mitsuya
Masatoshi
M
Takai
Yoshihiro
Y
Yamada
Shogo
S
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects; D012007:Rectum / Q000528:radiation effects*
D000726:Androgen Antagonists; D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors